-
-
-
-
-
-
-
ImmunityBio (IBRX) Reports Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders
-
-
-
-
-
-
-
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
-
-
-
-
-
-
-
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
-
15,671 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

